Haseeb Ahmad – Country President, Novartis UK
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Address: Novartis Pharmaceuticals UK Limited, Frimley Business Park, Camberley, Surrey, GU16 7SR, United Kingdom
Tel: +44 (0)1276 692255
Web: http://www.novartis.co.uk/index.shtml
Novartis UK is the UK affiliate of Swiss based Novartis AG – one of the largest and most widely respected pharmaceutical companies in the world. This pioneering and innovative company came about through the merger, in 1996, of two key Swiss pharmaceutical organisations, Ciba Geigy and Sandoz.
Headquartered in Basel, Novartis employs nearly 100,000 people worldwide and has a presence in over 140 countries. Novartis has a well-earned reputation for introducing innovative and effective medicines for disease areas in need of new therapies – particularly in oncology, transplantation and ophthalmology. The company is also known for producing new and ever-more efficient medicines for the more common cardiovascular and respiratory diseases, as well as for diseases affecting the brain.
Novartis currently has a total of 145 development projects in various stages of clinical development, including potential new products and potential new indications or formulations for existing products.
x Cardiovascular and Metabolism
x Hypertension, Diabetes, Atherosclerosis
x Integrated Speciality Medicines
x Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergies
x Infectious diseases, Transplantation and Immunology
x Organ transplants
x Neuroscience
x Alzheimer’s, Parkinson’s, Epilepsy, Multiple sclerosis
x Ophthalmics
x Age-related macular degeneration, Dry eye Haematologic and solid tumour diseases
Novartis Oncology aims to improve and extend the lives of patients with cancer. It has a wide range of therapy areas, and a broad pipeline of new products and new indications.
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease.…
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed…
Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James…
Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse…
With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland,…
After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR…
See our Cookie Privacy Policy Here
